YU49199B - Nova farmaceutska formulacija magnezijum omeprazola i postupak za njeno dobijanje - Google Patents

Nova farmaceutska formulacija magnezijum omeprazola i postupak za njeno dobijanje

Info

Publication number
YU49199B
YU49199B YU43794A YU43794A YU49199B YU 49199 B YU49199 B YU 49199B YU 43794 A YU43794 A YU 43794A YU 43794 A YU43794 A YU 43794A YU 49199 B YU49199 B YU 49199B
Authority
YU
Yugoslavia
Prior art keywords
omeprazole
magnesium
salt
manufacture
pharmaceutical formulation
Prior art date
Application number
YU43794A
Other languages
English (en)
Other versions
YU43794A (sh
Inventor
Inga Siv Bengtsson
Kurt Ingmar Lövgren
Original Assignee
Aktiebolaget Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU49199(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aktiebolaget Astra filed Critical Aktiebolaget Astra
Publication of YU43794A publication Critical patent/YU43794A/sh
Publication of YU49199B publication Critical patent/YU49199B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Oralna formulacija sa gastroinertnom prevlakom koja sadrži magnezijumovu so omeprazola kao materijal jezgra, jedan ili više međuslojeva i jedan ili više slojeva gastroinertne prevlake, naznačen time, što materijal jezgra sadrži magnezijumovu so omeprazola koja ima stepen kristaličnosti koji je viši od 70% određen difrakcijom X-zraka na prahu, i dobijen je u stupnjevima tretiranja omeprazola ili njegove soli sa magnezijum alkoholatom u rastvoru, odvajanja neorganske soli iz reakcione smeše, kristalizacije magnezijum omeprazola i izolovanja kristainog magnezijum omeprazola. Prijava sadrži još 14 zavisnih zahteva.
YU43794A 1993-07-09 1994-07-08 Nova farmaceutska formulacija magnezijum omeprazola i postupak za njeno dobijanje YU49199B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302395A SE9302395D0 (sv) 1993-07-09 1993-07-09 New pharmaceutical formulation

Publications (2)

Publication Number Publication Date
YU43794A YU43794A (sh) 1997-07-31
YU49199B true YU49199B (sh) 2004-09-03

Family

ID=20390587

Family Applications (1)

Application Number Title Priority Date Filing Date
YU43794A YU49199B (sh) 1993-07-09 1994-07-08 Nova farmaceutska formulacija magnezijum omeprazola i postupak za njeno dobijanje

Country Status (40)

Country Link
US (1) US5690960A (sh)
EP (1) EP0706378B1 (sh)
JP (1) JP3665334B2 (sh)
KR (1) KR100350203B1 (sh)
CN (1) CN1126946A (sh)
AT (1) ATE231719T1 (sh)
AU (1) AU681686B2 (sh)
BR (1) BR9406941A (sh)
CA (1) CA2166483C (sh)
CZ (1) CZ290323B6 (sh)
DE (1) DE69432076T2 (sh)
DK (1) DK0706378T3 (sh)
DZ (1) DZ1794A1 (sh)
EE (1) EE03148B1 (sh)
EG (1) EG22373A (sh)
ES (1) ES2191682T3 (sh)
FI (1) FI114008B (sh)
HK (1) HK1008299A1 (sh)
HR (1) HRP940386B1 (sh)
HU (1) HU226779B1 (sh)
IL (1) IL110189A0 (sh)
IS (1) IS2034B (sh)
LV (1) LV13140B (sh)
MA (1) MA23258A1 (sh)
MX (1) MX9405219A (sh)
MY (1) MY128809A (sh)
NO (1) NO315146B1 (sh)
NZ (1) NZ268694A (sh)
PL (1) PL175210B1 (sh)
RU (1) RU2138254C9 (sh)
SA (1) SA94150057B1 (sh)
SE (1) SE9302395D0 (sh)
SG (1) SG52365A1 (sh)
SI (1) SI0706378T1 (sh)
SK (1) SK281105B6 (sh)
TN (1) TNSN94078A1 (sh)
UA (1) UA43342C2 (sh)
WO (1) WO1995001783A1 (sh)
YU (1) YU49199B (sh)
ZA (1) ZA944934B (sh)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
HUT78132A (hu) * 1994-07-08 2000-06-28 Astra Aktiebolag Omeprazol magnéziumsóját tartalmazó új orális gyógyszerforma
PL180395B1 (pl) * 1994-07-08 2001-01-31 Astra Ab Doustna farmaceutyczna tabletkowana postac dawkowania oraz sposób wytwarzania doustnej farmaceutycznej tabletkowanej postaci dawkowania PL PL PL PL PL PL PL PL PL PL
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
PL332503A1 (en) * 1996-09-24 1999-09-13 Lilly Co Eli Coated particles containing preparation
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
KR20010012402A (ko) 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO1999027917A1 (de) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
ES2373864T3 (es) * 1998-04-20 2012-02-09 Eisai R&D Management Co., Ltd. Composición estabilizada que contiene un compuesto de tipo bencimidazol.
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
NZ511169A (en) 1998-11-18 2003-06-30 Astrazeneca Ab Process for making substituted sulphinyl heterocycles containing an imidazole moiety
US6365128B1 (en) * 1998-12-18 2002-04-02 Medical Defence Technologies, Llc Monitoring gastrointestinal function to guide care of high risk patients
EP1244430A4 (en) * 1999-03-29 2004-01-14 Wyeth Corp COATING SYSTEM
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
WO2001028559A1 (fr) 1999-10-20 2001-04-26 Eisai Co., Ltd. Procede de stabilisation de composes benzimidazoles
EP1706397A4 (en) * 2000-05-15 2007-08-01 Ranbaxy Lab Ltd AMORPHOUS FORM OF OMEPRAZOLE SALTS
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
CA2463690C (en) 2001-10-17 2011-08-23 Takeda Chemical Industries, Ltd. Granules containing acid-unstable chemical in large amount
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
GB2392839A (en) * 2002-03-08 2004-03-17 Bakulesh Mafatlal Khamar Use of Mycobacterium w in the treatment of tuberculosis
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
ES2299710T3 (es) * 2002-08-02 2008-06-01 Ratiopharm Gmbh Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion.
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
ITMI20030616A1 (it) * 2003-03-28 2004-09-29 Acme Drugs S R L Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
EP1660052A2 (en) * 2003-09-03 2006-05-31 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP1845982A2 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
EP2275088B2 (en) 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Method for producing granules
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP2068837A2 (en) * 2006-07-28 2009-06-17 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009136398A2 (en) * 2008-05-06 2009-11-12 Dexcel Ltd Stable benzimidazole formulation
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
JP2012502015A (ja) 2008-09-09 2012-01-26 アストラゼネカ・アクチエボラーグ 必要がある患者に医薬組成物を送達するための方法
ES2411972T5 (es) 2009-01-09 2021-10-27 Fwp Ip Aps Formulación farmacéutica que comprende uno o más ésteres de ácido fumárico en una matriz de erosión
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
WO2012174102A2 (en) 2011-06-14 2012-12-20 Medical Defense Technologies, Llc. Methods and apparatus for guiding medical care based on detected gastric function
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
CN103735526A (zh) * 2013-08-08 2014-04-23 上海海虹实业(集团)巢湖今辰药业有限公司 奥美拉唑镁肠溶片及其制作方法
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
JPWO2021153525A1 (sh) 2020-01-27 2021-08-05
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
CN113350313B (zh) * 2021-06-23 2023-08-11 福建金山生物制药股份有限公司 一种艾司奥美拉唑镁延释制剂及其制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation

Also Published As

Publication number Publication date
HUT75306A (en) 1997-05-28
DK0706378T3 (da) 2003-05-05
DE69432076D1 (de) 2003-03-06
UA43342C2 (uk) 2001-12-17
SG52365A1 (en) 1998-09-28
HU9503874D0 (en) 1996-02-28
NO960067L (no) 1996-01-05
EE03148B1 (et) 1999-02-15
AU7198294A (en) 1995-02-06
HU226779B1 (en) 2009-10-28
HRP940386A2 (en) 1997-02-28
JP3665334B2 (ja) 2005-06-29
SA94150057B1 (ar) 2006-10-03
SE9302395D0 (sv) 1993-07-09
EG22373A (en) 2002-12-31
WO1995001783A1 (en) 1995-01-19
TNSN94078A1 (fr) 1995-04-25
CZ290323B6 (cs) 2002-07-17
IS2034B (is) 2005-08-15
BR9406941A (pt) 1996-09-10
FI114008B (fi) 2004-07-30
ES2191682T3 (es) 2003-09-16
NO315146B1 (no) 2003-07-21
EP0706378A1 (en) 1996-04-17
MA23258A1 (fr) 1995-04-01
HRP940386B1 (en) 2003-10-31
HK1008299A1 (en) 1999-05-07
DE69432076T2 (de) 2003-10-16
FI960102A0 (fi) 1996-01-09
SK281105B6 (sk) 2000-12-11
PL312441A1 (en) 1996-04-29
MX9405219A (es) 1995-01-31
EP0706378B1 (en) 2003-01-29
ZA944934B (en) 1995-02-20
ATE231719T1 (de) 2003-02-15
NZ268694A (en) 1997-05-26
DZ1794A1 (fr) 2002-02-17
CA2166483A1 (en) 1995-01-19
SK2196A3 (en) 1997-04-09
JPH08512316A (ja) 1996-12-24
NO960067D0 (no) 1996-01-05
US5690960A (en) 1997-11-25
MY128809A (en) 2007-02-28
AU681686B2 (en) 1997-09-04
CN1126946A (zh) 1996-07-17
YU43794A (sh) 1997-07-31
SI0706378T1 (en) 2003-06-30
IL110189A0 (en) 1994-10-21
IS4187A (is) 1995-01-10
PL175210B1 (pl) 1998-11-30
RU2138254C1 (ru) 1999-09-27
CA2166483C (en) 1997-09-16
CZ7096A3 (en) 1996-06-12
KR100350203B1 (ko) 2002-12-28
FI960102A (fi) 1996-01-09
RU2138254C9 (ru) 2009-09-27
LV13140B (en) 2004-08-20

Similar Documents

Publication Publication Date Title
YU49199B (sh) Nova farmaceutska formulacija magnezijum omeprazola i postupak za njeno dobijanje
FR2576592B1 (fr) Procede de formation d'une masse refractaire et composition de matiere destinee a former une telle masse par projection
UA43343C2 (uk) Магнієва сіль омепразолу, спосіб її одержання, фармацевтична композиція, спосіб лікування
DE69213482D1 (de) Beschichtungszusammensetzung zum Herstellen von isolierenden Schichten und Masken
HUT58288A (en) Process for producing heterocyclic guanidines and pharmaceutical compositions containing them
JPS5692272A (en) N-pyridylaniline compound, its preparation and control agent against injurious organisms containing the same
BE896724A (fr) Procede de traitement thermique d'une fraction de plasma, produit obtenu et composition pharmaceutique le contenant.
IL105827A0 (en) Thienobenzodiazepines,their preparation and pharmaceutical compositions containing them
ATE176472T1 (de) Verfahren zur herstellung von nalbuphin das wenig des 6-beta-epimers enthält
FI925944A (fi) Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt
DE69301186D1 (de) Gleichseitiges Verfahren zur Herstellung von Bildern durch Wärmeübertragung
AT361906B (de) Verfahren zur herstellung von neuen 2,4,6- trijodbenzonitrilen sowie deren estern, saeure- amiden und salzen
ATE6031T1 (de) Arzneimittel zur oralen verabreichung und verfahren zu seiner herstellung.
AT381092B (de) Verfahren zur herstellung von neuen substituierten pyrrolo-(2,1-b)-chinazolinen und pyrido(2,1-b)- chinazolinen, ihren isomeren und deren gemischen und ihren pharmazeutisch unbedenklichen salzen
ZA888663B (en) Substituted derivatives of 20,21-dinoreburanamenine,their preparation process and the new intermediates thus obtained,their use as medicaments and the pharmaceutical compositions containing them
ES2107082T3 (es) Acidos 6-piperazinil-1h-pirazolo(3,4-b)piridina-3-carboxilicos, esteres, amidas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
JPS5220398A (en) Process for manufacturing hydrogen-type synthetic inorganic laminate s tructures
SE8402297L (sv) Pyridyl-n-oxider
DE3261759D1 (en) Novel ester of 1,1-dioxopenicillanic acid, process for production thereof, and use thereof as beta-lactamase inhibitor
JPS5695143A (en) 4-substituted nonanal and its preparation
JPS5538363A (en) Preparation of optically active n-mercaptoacyl-imino acid
HUT36664A (en) Process for production of alpha-alkil-tio-cinnamic-acid nitrils and pesticides consisting of such compounds as agents
RU94046014A (ru) Диаминовые соли клавулановой кислоты
MD282B1 (ro) Procedeu de preparare a amestecului de izomeri ai zipermetrinei sub forma de produs cristalin stabilizat
TH2533EX (th) ขบวนการผลิตอีแนนทีโอเมอร์เป็นคู่ๆ ที่เฉพาะเจาะจงของสาร อัลฟา-ไชยาโน-3-พีนอกซี-4-ฟลูออโร-เบนซลเพอร์มีเธรท